Wire · opportunities
FDA Approves Talazoparib Plus Enzalutamide for Metastatic, HRR+ APMN/S Prostate Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 October 2026 · Fusion42 review
The FDA approved talazoparib combined with enzalutamide for metastatic HRR-positive androgen pathway modulation–naive or sensitive prostate cancer based on positive results from the phase 3 TALAPRO-3 trial showing significant improvement in radiographic progression-free survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it.
◆ ◆ The Wire takeaway
You can now target metastatic prostate cancer patients with HRR mutations using a new FDA-approved drug combo that improves disease control. This opens a direct treatment route and demands swift diagnostic partnerships or investment in mutation testing.
◆ Coverage
7 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics